Page last updated: 2024-11-13
furosemide glucuronide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
furosemide glucuronide: urinary metabolite of furosemide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21123459 |
| MeSH ID | M0110539 |
Synonyms (16)
| Synonym |
|---|
| furosemide glucuronate |
| furosemide acyl glucuronide |
| 72967-59-0 |
| beta-d-glucopyranuronic acid, 1-(5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoate) |
| unii-b6c1sx3fij |
| b6c1sx3fij , |
| furosemide glucuronide |
| furosemide acyl-beta-d-glucuronide |
| W-203659 |
| (2s,3s,4s,5r,6s)-6-[4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid |
| .beta.-d-glucopyranuronic acid, 1-(5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoate) |
| furosemide acyl-?-d-glucuronide |
| furosemide acyl-?-d-glucuronide allyl ester |
| beta-d-glucopyranuronic acid, 1-[5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoate] |
| DTXSID401120112 |
| (2s,3s,4s,5r,6s)-6-((4-chloro-2-((furan-2-ylmethyl)amino)-5-sulfamoylbenzoyl)oxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-carboxylic acid |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " A pharmacokinetic profile of furosemide is shown, and some preliminary pharmacokinetic parameters of furosemide obtained from one human volunteer are given." | ( Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. van den Biggelaar-Martea, M; Verwey-van Wissen, CP; Vree, TB, 1994) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two kinds of dosage forms (tablets and retarded capsules) of furosemide (F) were compared in vitro dissolution profile and in vivo absorption studies." | ( Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects. Kenmotsu, H; Kiuchi, T; Satoh, H; Sekikawa, H; Takada, M; Terashima, Y; Yagi, N, 1996) | 0.29 |
| " After each dosage of furosemide, there is first a short stimulation of urine flow (4 h), which is followed by a 3-day recovery period of the body." | ( Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans. van der Ven, AJ; Vree, TB, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 1 (7.14%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||